Abnormal Involuntary Movement

The most common adverse reactions seen with pramipexole and ropinirole include nausea, dizziness, postural hypotension, hallucinations, somnolence, vomiting, confusion, visual disturbances, abnormal involuntary movements, and headache... 

Abnormal involuntary movements (AIMs), manifest mainly as dyskinesias at the peak plasma level of dopa. 

Symptom Rating Scale (ESRS). Akathisia is commonly monitored by the Barnes Akathisia Scale (BAS). The emergence of dyskinesias (writhing or involuntary movements) could represent the emergence of TD. Monitor for TD at least annually, and if FGAs are used patients should be evaluated at each visit. The most commonly used instrument to measure these symptoms is the Abnormal Involuntary Movement Scale (AIMS). 

Dyskinesia Abnormal involuntary movements, which include dystonia, chorea, and akathisia. 

TD is sometimes irreversible and is characterized by abnormal involuntary movements occurring with chronic antipsychotic therapy. 

The Abnormal Involuntary Movement Scale (AIMS) and the Dyskinesia Identification System Condensed User Scale (DISCUS) should be used to screen (at baseline and at least quarterly) and can facilitate early detection of TD, but neither scale is diagnostic. 

An abnormal involuntary movement of the eyes. It may be rotational or horizontal or vertical plane. 

Lactation suppression 25 mg bid x 14-21 days Nausea, vertigo, confusion, abnormal involuntary movements, hallucina-tbns, depression prevent pregnancy. 

Ora/-Adverse reactions requiring discontinuation include Pulmonary infiltrates or fibrosis paroxysmal ventricular tachycardia CHF elevation of liver enzymes visual disturbances solar dermatitis blue discoloration of skin hyperthyroidism hypothyroidism. Adverse reactions occurring in at least 3% of patients include CFIF Gl complaints (nausea, vomiting, constipation, anorexia) dermatologic reactions (photosensitivity, solar dermatitis) neurologic problems (malaise, fatigue, tremor/abnormal involuntary movements, lack of coordination, abnormal gait/ataxia, dizziness, paresthesias) abnormal liver function tests. 

Adverse reactions may include abdominal pain, abnormal involuntary movements, abnormal liver function tests, aching joints or muscles, acute urinary retention, adenopathy or lymphadenopathy, aggravation of coronary artery disease, aggravation of disseminated lupus erythematosus, agranulocytosis, albuminuria, alopecia, alterations in pigmentation, anorexia, aplastic anemia, arrhythmias, asthma, AV P.729... 

Observe closely for signs of fardive dyskinesia (abnormal involuntary movement scale)... 

Neurological Extrapyramidal side effects, sedation, seizures Dopamine 2, histamine Examine for Parkinsonism, akath-isia, and abnormal involuntary movements at each visit Baseline electroencephalogram if treated with clozapine. 

It is recommended that neurological side effects be monitored carefully throughout the course of antipsychotic treatment. Rating scales can assist in monitoring for EPS and the involuntary movements seen in tardive dyskinesia. These include the Neurological Rating Scale (Simpson and Angus, 1970), the Barnes Akathisia Scale (Barnes, 1989), and the Abnormal Involuntary Movement Scale ([AIMS] National Institute of Mental Health, 1985). 

National Institute for Mental Health. (1985) Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 21 1077—1080. 

The most common adverse events associated with buspirone use include dizziness, headache, nausea, ner-vounsness, lightheadedness, and agitation. These adverse effects decrease over time. Buspirone does not cause seizures or abnormal involuntary movements or impair psychomotor performance. 

TD presents with abnormal involuntary movements, usually associated with chronic (i.e., longer than 2 years) antipsychotic therapy (456). Although there is some debate whether the antipsychotics are either necessary or sufficient to produce this syndrome in psychiatric patients, the consensus is that they at least play an... 

TD varies in presentation, and should always be considered in the differential diagnosis of any abnormal involuntary movements in patients exposed to antipsychotics or DA-receptor blocking agents used for other medical conditions (e.g., prochlorperazine or metoclopramide). 

Because very few patients had abnormal involuntary movements at baseline, the ability of quetiapine to ameliorate such movements was inconclusive. 

Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979 136 317-320. 

The etiology of progressive death of dopaminergic neurons in substantia nigra of Parkinson s disease brains remains unclear. Dopamine deficiency in Parkinson s disease is commonly treated with L-dopa and carbidopa, a periphera dopa decarboxylase inhibitor (Sinemet). Since its introduction, L-dopa has been shown to be effective in treating Parkinson s disease. However, high concentrations of L-dopa produce side effects such as psychosis, on-off effects, abnormal involuntary movements, and akinetic crisis. 

Abnormal involuntary movements appear in approximately 50% of patients within the first few months of the commencement of L-dopa therapy, these effects being correlated with the dose of the drug and the degree of clinical improvement. The frequency of the abnormal involuntary movements increases with the duration of administration and can reach 80% of patients after 1 year of therapy. Such abnormal movements are presumed to be due to postsynaptic dopamine receptor hyperactivity and include buccolingual movements, grimacing, head-bobbing, and various choreiform and dystonic movements of the extremities. Tolerance does not appear to develop to these effects and there is no known treatment apart from reducing the dose of L-dopa, a situation which inevitably leads to the likelihood of a return of the Parkinsonian symptoms. 

Crow, T. J., Cross, A. J., Johnstone, E. C., Owen, F., Owens, D. G., Waddington, J. L. 1982, Abnormal involuntary movements in schizophrenia are they related to the disease process or its treatment Are they associated with changes in dopamine receptors , J.Clin.Psychopharmacol., vol. 2, no. 5, pp. 336-340. 

A clinical study of hospitalized drug-treated patients found many suffering from mental deterioration typical of a chronic organic brain syndrome that the researchers labeled dysmentia (Wilson et ah, 1983). Tardive dysmentia consists of unstable mood, loud speech, and [inappropriately close] approach to the examiner. It is probably a variant of hypomanic dementia.1 The mental abnormalities in the study by Wilson et al. (1983) correlated positively with TD symptoms measured on the Abnormal Involuntary Movement Scale. In addition, length of neuroleptic treatment correlated with three measures of dementia unstable mood, loud speech, and euphoria. The authors stated, It is our hypothesis that certain of the behavioral changes observed in schizophrenic patients over time represent a behavioral equivalent of tardive dyskinesia, which we will call tardive dysmentia (p. 188). The tendency in the literature, perhaps in search of a euphemism, has been to use the term tardive dysmentia even when a full-blown dementing syndrome is described. 

Gervin M, Browne S, Lane A, Clarke M, Waddington JL, Larkin C, O Callaghan E. Spontaneous abnormal involuntary movements in first-episode schizophrenia and... 

The efficacy and safety of buspirone have been evaluated in the management of anxiety and irritability in 22 children with pervasive developmental disorders. One child developed abnormal involuntary movements of the mouth, cheeks, and tongue after having taken buspirone 20 mg/day for 10 months. No other drugs were prescribed. The abnormal movements disappeared completely within 2 weeks of withdrawal of buspirone. Other adverse effects... 

---